NCT03920540View on ClinicalTrials.gov

A Study of GC1111 in Hunter Syndrom Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions
Hunter Syndrome
Interventions
COMBINATION_PRODUCT

GC1111

GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.

COMBINATION_PRODUCT

Comparator

Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.

Trial Locations (1)

Unknown

Samsug Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY